Detalles de la búsqueda
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37163621
2.
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Blood
; 141(5): 519-528, 2023 02 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36084320
3.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37172204
4.
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
Blood
; 142(13): 1131-1142, 2023 09 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37363833
5.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Lancet Oncol
; 2024 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38889735
6.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 25(6): 744-759, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38821083
7.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(12): 1423-1433, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37944541
8.
Risk of cancer after ST-segment-elevation myocardial infarction.
Eur J Epidemiol
; 38(8): 853-858, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36947265
9.
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(6): 818-828, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35654052
10.
The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
Int J Cancer
; 151(4): 616-622, 2022 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35403708
11.
Association Between Geriatric Assessment and Post-Chemotherapy Functional Status in Older Patients with Cancer.
Oncologist
; 27(11): e878-e888, 2022 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35861263
12.
Human CXCR5+ PD-1+ CD8 T cells in healthy individuals and patients with hematologic malignancies.
Eur J Immunol
; 51(3): 703-713, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33098668
13.
Unmet supportive care needs, anxiety and depression in haematology patients during watch-and-wait.
Psychooncology
; 31(2): 176-184, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34459065
14.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34529931
15.
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.
Blood
; 134(1): 44-58, 2019 07 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31076448
16.
The accuracy of mean corpuscular volume guided anaemia classification in primary care.
Fam Pract
; 38(6): 735-739, 2021 11 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34345918
17.
2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab.
Cardiovasc Ultrasound
; 19(1): 35, 2021 Nov 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34753503
18.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet
; 394(10192): 29-38, 2019 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31171419
19.
Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
Blood
; 132(21): 2260-2272, 2018 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30213872
20.
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Haematologica
; 105(6): 1650-1659, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31515355